Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
Methods are provided for treating hyponatremia, employing an SGLT2 inhibitor alone, or in combination with a supply of carbohydrate, and/or in combination with a diuretic agent. Additionally, compositions comprising an SGLT2 inhibitor, optionally with a supply of carbohydrate, and/or a combination of an SGLT2 inhibitor and a diuretic agent are provided in the instant invention and are provided for use in the inventive methods.
1. A method for treating hyponatremia in a mammal, the hyponatremia being associated with reduced plasma osmolality, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor, wherein the SGLT2 inhibitor is
or a prodrug ester thereof or a propylene glycol solvate thereof.
2. The method according to claim 1 , wherein the hyponatremia is chronic hyponatremia.
3. The method according to claim 1 , said method further comprising administering to the mammal a supply of carbohydrate, wherein the supply of carbohydrate is administered before, after, or concurrently with the SGLT2 inhibitor.
4. The method according to claim 1 , wherein plasma sodium concentration of the mammal is below 135 mmol/L.
5. A method for treating hyponatremia in a mammal suffering from water intoxication, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor, wherein the SGLT2 inhibitor is
or a prodrug ester thereof or a propylene glycol solvate thereof.
6. The method according to claim 1 , wherein the mammal suffers from water retention.
7. The method according to claim 1 , further comprising administering to the mammal a diuretic agent wherein the diuretic agent is administered before, after, or concurrently with the SGLT2 inhibitor.
8. The method according to claim 1 , wherein the diuretic agent is an anti-diuresis hormone (ADH) antagonist.
9. The method according to claim 1 , wherein the SGLT2 inhibitor is administered in an amount sufficient to reduce hyponatremia without inducing hypoglycemia.
10. The method according to claim 1 wherein the SGLT2 inhibitor is
11. The method according to claim 1 , wherein the administration of the SGLT2 inhibitor treats the hyponatremia by increasing urine volume.
12. A method for treating hypervolemic hyponatremia in a mammal, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor, wherein the SGLT2 inhibitor is
or a prodrug ester thereof or a propylene glycol solvate thereof, wherein the administration of the SGLT2 inhibitor treats the hyponatremia by increasing urine volume.
13. A method for treating hyponatremia in a mammal not suffering from hyperglycemia, the method comprising administering to the mammal in need of such treatment a therapeutically effective amount of a sodium glucose transporter 2 (SGLT2) inhibitor, wherein the SGLT2 inhibitor is
or a prodrug ester thereof or a propylene glycol solvate thereof.
14. The method according to claim 3 , wherein the supply of carbohydrate is administered concurrently with the SGLT2 inhibitor at a rate in the range of about 30 to about 270 g concurrently-administered carbohydrate per day.
15. The method according to claim 5 wherein the SGLT2 inhibitor is
16. The method according to claim 5 , wherein plasma sodium concentration of the mammal is below 135 mmol/L.
17. The method according to claim 5 , wherein the SGLT2 inhibitor is administered in an amount sufficient to reduce hyponatremia without inducing hypoglycemia.
18. The method according to claim 12 wherein the SGLT2 inhibitor is
19. The method according to claim 12 , wherein plasma sodium concentration of the mammal is below 135 mmol/L.
20. The method according to claim 12 , wherein the SGLT2 inhibitor is administered in an amount sufficient to reduce hyponatremia without inducing hypoglycemia.
21. The method according to claim 13 wherein the SGLT2 inhibitor is
22. The method according to claim 13 , wherein plasma sodium concentration of the mammal is below 135 mmol/L.
23. The method according to claim 13 , wherein the SGLT2 inhibitor is administered in an amount sufficient to reduce hyponatremia without inducing hypoglycemia.